Frank Leonard, CEO of NovoCure Limited (NVCR), conducted a notable open-market sale of 34,273 shares, valued at approximately $615,000, on June 4, 2026. This transaction is the largest individual sale by Leonard to date, constituting 6.94% of his direct holdings. Despite the elevated sale size, it aligns with the reduced capacity from prior transactions.
NovoCure has faced mixed performance; while its stock has dropped by about 63% over the past three years, it has gained around 30% year-to-date, surpassing the S&P 500’s 9% increase. The company’s revenue rose from $500 million in 2023 to nearly $675 million, bolstered by FDA approval for its pancreatic cancer treatment, Optune Pax. Investors wary of volatility in the biotech sector might consider diversifying with biotech ETFs like the SPDR S&P Biotech ETF (XBI).
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/coverage/filings/2026/06/09/ceo-sells-34k-shares-of-biotech-stock-valued-at-usd615-000-according-to-latest-sec-filing/
